Comparative Pharmacology
Head-to-head clinical analysis: PROTRIPTYLINE HYDROCHLORIDE versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTRIPTYLINE HYDROCHLORIDE versus VIVACTIL.
PROTRIPTYLINE HYDROCHLORIDE vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. May also downregulate beta-adrenergic and serotonin receptors.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
15 mg orally 3 to 4 times daily, not to exceed 60 mg per day.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 54-92 hours (mean ~74 hours); due to long half-life, steady-state is reached in 11-18 days.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Primarily renal (50-70% as metabolites, <5% unchanged); biliary/fecal elimination accounts for ~10-20%.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant